Fibromyalgia, milnacipran and experimental pain modulation: study protocol for a double blind randomized controlled trial.

ABSTRACT:

Background

The prevalence of fibromyalgia increases worldwide and is characterized by widespread and chronic pain. Treatment is difficult and includes both drug and non-drug approaches. Milnacipran, an antidepressant, is used for fibromyalgia, with a possible beneficial effect on central pain modulation. Our hypothesis is that the efficacy of milnacipran in fibromyalgia depends on the performance of pain inhibitory controls.

Methods/design

A randomized, double blind, clinical trial (NCT01747044) with two parallel groups, in 48 women with fibromyalgia, is planned in the Clinical Pharmacology Center, University Hospital, Clermont-Ferrand, France. Conditioned pain modulation (estimated with thermal stimuli using a numeric pain rating scale), the primary endpoint measure, is eva

SUBMITTER: Macian N 

PROVIDER: S-EPMC4393595 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature